Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-19

Clinical Trial Update: Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment [Phase 3]

View source ↗

Summary

Phase 3 trial comparing evolocumab to LDL-C apheresis in patients already receiving apheresis; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Evolocumab (evolocumab)

Snippet

Sponsor: Amgen | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2017-09-19